Literature DB >> 29934356

Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes.

Alberto Alvarez-Larran1, Daniel Martínez2, Leonor Arenillas3, Ariadna Rubio4, Eduardo Arellano-Rodrigo5, Juan Carlos Hernández Boluda6, Natalia Papaleo3, Gonzalo Caballero7, Clara Martínez8, Francisca Ferrer-Marín9, María Isabel Mata10, Manuel Pérez-Encinas11, María Antonia Durán12, José María Alonso13, Gonzalo Carreño-Tarragona14, Juan Manuel Alonso15, Soledad Noya16, Elena Magro17, Raúl Pérez18, Mónica López-Guerra2, Irene Pastor-Galán6, Francisco Cervantes1, Carlos Besses4, Luis Colomo3, María Rozman2.   

Abstract

AIM: To characterise the clinical and histological features of MPL-mutated essential thrombocythaemia (ET). PATIENTS AND METHODS: Bone marrow biopsies of 175 patients with ET were centrally reviewed according to the 2016 WHO classification, including 42 cases with MPL mutation, 98 JAK2V617F-mutated and 35 CALR-mutated. Clinical and histological features were compared among the three genotypes included in the current 2016 WHO classification and among the different types of MPL mutations.
RESULTS: Patients with MPL-mutated ET were significantly older than those with the other genotypes. Haematological values at diagnosis were similar among MPL-mutated and CALR-mutated ET, with both genotypes showing higher platelet counts and lower haemoglobin values than ET with JAK2V617F genotype. In the bone marrow, the median number of megakaryocytes was higher in MPL and CALR than in JAK2V617F genotype (16, 19 and 14 megakaryocytes per ×20 power field, respectively, p=0.004). Histological features of prefibrotic myelofibrosis were rarely observed in MPL genotype, whereas sinusoidal hyperplasia, dense clusters of megakaryocytes and reticulin fibrosis were more frequent in CALR-mutated ET, with 11% of such cases fulfilling WHO 2016 histological criteria of prefibrotic myelofibrosis. With a median follow-up of 3.5 years, no significant differences were seen among genotypes regarding survival, vascular complications or myelofibrotic transformation. There were no significant differences in the clinical data or in the histological characteristics depending on the type of MPL mutation.
CONCLUSION: MPL and CALR ET genotypes share clinical and histological characteristics. In contrast to CALR genotype, features of prefibrotic myelofibrosis are uncommon in MPL-mutated ET. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  diagnostic hematology; essential thrombocythemia; genetics; histopathology; myeloproliferative neoplasms

Mesh:

Substances:

Year:  2018        PMID: 29934356     DOI: 10.1136/jclinpath-2018-205227

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

1.  Familial thrombocythaemia - a distinct entity from essential thrombocythaemia.

Authors:  James Bussel; Nicole Kucine
Journal:  Br J Haematol       Date:  2021-08-02       Impact factor: 8.615

Review 2.  Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?

Authors:  Daniela Cilloni; Jessica Petiti; Valentina Rosso; Giacomo Andreani; Matteo Dragani; Carmen Fava; Giuseppe Saglio
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

Review 3.  Essential Thrombocythemia in Children and Adolescents.

Authors:  Maria Caterina Putti; Irene Bertozzi; Maria Luigia Randi
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

4.  MPL-mutated essential thrombocythemia: a morphologic reappraisal.

Authors:  Natasha Szuber; Curtis A Hanson; Terra L Lasho; Christy Finke; Rhett P Ketterling; Animesh Pardanani; Naseema Gangat; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-11-20       Impact factor: 11.037

5.  Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis.

Authors:  Erpeng Yang; Mingjing Wang; Ziqing Wang; Yujin Li; Xueying Wang; Jing Ming; Haiyan Xiao; Richeng Quan; Weiyi Liu; Xiaomei Hu
Journal:  Ann Hematol       Date:  2021-08-12       Impact factor: 3.673

6.  Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).

Authors:  Razan Hayati Zulkeflee; Zefarina Zulkafli; Muhammad Farid Johan; Azlan Husin; Md Asiful Islam; Rosline Hassan
Journal:  Int J Environ Res Public Health       Date:  2021-07-16       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.